Cross-Sectional Analysis of Clinical Trial Availability and North Carolina Neighborhood Social Vulnerability

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Matthew Jansen

Other Relationship: American Cancer Society

Samuel M. Rubinstein

Honoraria: Sanofi

Consulting or Advisory Role: Roche, Janssen, EUSA Pharma

Tanya M. Wildes

Honoraria: Carevive Systems

Consulting or Advisory Role: Seattle Genetics, Carevive Systems, Sanofi

Research Funding: Janssen Oncology (Inst)

Sascha A. Tuchman

Honoraria: Shattuck Labs, Janssen

Speakers' Bureau: Celgene

Research Funding: Karyopharm Therapeutics (Inst), Janssen (Inst), Sanofi (Inst), Bristol Myers Squibb/Celgene (Inst), AbbVie (Inst)

Eben I. Lichtman

Consulting or Advisory Role: Lilly (I), ChemoCentryx (I)

Research Funding: Pfizer (I)

No other potential conflicts of interest were reported.